Overview
Availability
- Associate Professor Simone M Goldinger is:
- Available for supervision
Qualifications
- Bachelor (Honours) of Medicine, University of Zurich
- Masters (Research) of Medicine and Surgery and Medical Science, University of Zurich
- Doctoral (Research), University of Zurich
- Professional Doctorate, University of Zurich
- Fellow, Australasian College of Dermatologists, Australasian College of Dermatologists
Works
Search Professor Simone M Goldinger’s works on UQ eSpace
2012
Journal Article
Atypical Melanocytic Proliferations and New Primary Melanomas in Patients With Advanced Melanoma Undergoing Selective <i>BRAF</i> Inhibition
Zimmer, Lisa, Hillen, Uwe, Livingstone, Elisabeth, Lacouture, Mario E., Busam, Klaus, Carvajal, Richard D., Egberts, Friederike, Hauschild, Axel, Kashani-Sabet, Mohammed, Goldinger, Simone M., Dummer, Reinhard, Long, Georgina V., McArthur, Grant, Scherag, Andre, Sucker, Antje and Schadendorf, Dirk (2012). Atypical Melanocytic Proliferations and New Primary Melanomas in Patients With Advanced Melanoma Undergoing Selective BRAF Inhibition. Journal of Clinical Oncology, 30 (19), 2375-2383. doi: 10.1200/JCO.2011.41.1660
2012
Conference Publication
Cutaneous side effects (cAE) of vemurafenib (V): Single-center cohort study of 28 metastatic melanoma (mM) patients (pts)
Goldinger, Simone M., Rinderknecht, Jeannine Desiree, Belloni, Benedetta, Eggmann, Nina and Dummer, Reinhard (2012). Cutaneous side effects (cAE) of vemurafenib (V): Single-center cohort study of 28 metastatic melanoma (mM) patients (pts). 48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Chicago Il, Jun 01-06, 2012. ALEXANDRIA: AMER SOC CLINICAL ONCOLOGY.
2012
Journal Article
Cutaneous Lymphomas: Molecular Pathways Leading to New Drugs
Dummer, Reinhard, Goldinger, Simone M., Cozzio, Antonio, French, Lars E. and Karpova, Maria B. (2012). Cutaneous Lymphomas: Molecular Pathways Leading to New Drugs. Journal of Investigative Dermatology, 132 (3), 517-525. doi: 10.1038/jid.2011.370
2012
Journal Article
Ultraviolet A and Photosensitivity during Vemurafenib Therapy
Dummer, Reinhard, Rinderknecht, Jeannine and Goldinger, Simone M. (2012). Ultraviolet A and Photosensitivity during Vemurafenib Therapy. New England Journal of Medicine, 366 (5), 480-481. doi: 10.1056/NEJMc1113752
2012
Journal Article
First-line temozolomide combined with bevacizumab in metastatic melanoma: a multicentre phase II trial (SAKK 50/07)
von Moos, R., Seifert, B., Simcock, M., Goldinger, S. M., Gillessen, S., Ochsenbein, A., Michielin, O., Cathomas, R., Schlaeppi, M., Moch, H., Schraml, P. H., Mjhic-Probst, D., Mamot, C., Schoenewolf, N. and Dummer, R. (2012). First-line temozolomide combined with bevacizumab in metastatic melanoma: a multicentre phase II trial (SAKK 50/07). Annals of Oncology, 23 (2), 531-536. doi: 10.1093/annonc/mdr126
2012
Journal Article
Cutaneous Drug Eruptions Associated with the Use of New Oncological Drugs
Belloni, Benedetta, Schoenewolf, Nicola, Rozati, Sima, Goldinger, Simone M. and Dummer, Reinhard (2012). Cutaneous Drug Eruptions Associated with the Use of New Oncological Drugs. Adverse Cutaneous Drug Eruptions, 97, 191-202.
2011
Conference Publication
Final results of single-agent phase II study using the inhibitor of purine nucleoside phosphorylase (PNP) in patients suffering from advanced primary cutaneous t-cell lymphomas (CTCL)
Dummer, R., Duvic, M., Scarisbrick, J., Olsen, E., Goldinger, S., Hutchinson, K., Geskin, L., Illidge, T., Kim, Y., Giuliano, E. and Elder, J. (2011). Final results of single-agent phase II study using the inhibitor of purine nucleoside phosphorylase (PNP) in patients suffering from advanced primary cutaneous t-cell lymphomas (CTCL). MALDEN: WILEY-BLACKWELL.
2011
Conference Publication
Inhibition of the MEK-kinase pathway in advanced melanoma
Dummer, R., Goldinger, S., Turtschi, C., Gisler, S., Eggmann, N. and Rinderknecht, J. (2011). Inhibition of the MEK-kinase pathway in advanced melanoma. BASEL: KARGER.
2011
Conference Publication
An open-label pilot study of vemurafenib in previously treated metastatic melanoma patients with brain metastases
Dummer, R., Rinderknecht, J., Goldinger, S. M., Wagner, I., Mitchell, L., Veronese, M. L., Nick, S., Hilfiker, P. and Gobbi, S. (2011). An open-label pilot study of vemurafenib in previously treated metastatic melanoma patients with brain metastases. ALEXANDRIA: AMER SOC CLINICAL ONCOLOGY. doi: 10.1200/jco.2011.29.15_suppl.8548
2011
Journal Article
The antibacterial substance, taurolidine in the second/third-line treatment of very advanced stage IV melanoma including brain metastases: results of a phase 2, open-label study
Imhof, Laurence, Goldinger, Simone M., Baumann, Katrin, Schad, Karin, French, Lars E., Roethlisberger, Peter and Dummer, Reinhard (2011). The antibacterial substance, taurolidine in the second/third-line treatment of very advanced stage IV melanoma including brain metastases: results of a phase 2, open-label study. Melanoma Research, 21 (1), 80-83. doi: 10.1097/CMR.0b013e328341442d
2010
Conference Publication
Predictive and prognostic potential of angiogenic serum factors and circulating endothelial cells in metastatic melanoma patients receiving temozolamide plus bevacizumab (SAKK 50/07)
Fuerstenberger, G., Boneberg, E., Simcock, M., Dummer, R., Goldinger, S. M., Michielin, O., Seifert, B., Ochsenbein, A. F., Schlaeppi, M. R. and von Moos, R. (2010). Predictive and prognostic potential of angiogenic serum factors and circulating endothelial cells in metastatic melanoma patients receiving temozolamide plus bevacizumab (SAKK 50/07). ALEXANDRIA: AMER SOC CLINICAL ONCOLOGY. doi: 10.1200/jco.2010.28.15_suppl.8585
2010
Conference Publication
First-line temozolomide (TEM) combined with bevacizumab (BEV) in metastatic melanoma (MM): A multicenter phase II trial (SAKK 50/07)
Dummer, R., Michielin, O., Seifert, B., Ochsenbein, A. F., Cathomas, R., Schlaeppi, M. R., Simcock, M., Gillessen, S., Goldinger, S. M. and von Moos, R. (2010). First-line temozolomide (TEM) combined with bevacizumab (BEV) in metastatic melanoma (MM): A multicenter phase II trial (SAKK 50/07). ALEXANDRIA: AMER SOC CLINICAL ONCOLOGY. doi: 10.1200/jco.2010.28.15_suppl.8521
2009
Journal Article
Limited value of <SUP>18</SUP>F-FDG PET/CT and S-100B tumour marker in the detection of liver metastases from uveal melanoma compared to liver metastases from cutaneous melanoma
Strobel, K., Bode, B., Dummer, R., Veit-Haibach, P., Fischer, D. R., Imhof, L., Goldinger, S., Steinert, Hans C. and von Schulthess, G. K. (2009). Limited value of 18F-FDG PET/CT and S-100B tumour marker in the detection of liver metastases from uveal melanoma compared to liver metastases from cutaneous melanoma. European Journal of Nuclear Medicine and Molecular Imaging, 36 (11), 1774-1782. doi: 10.1007/s00259-009-1175-0
2009
Conference Publication
Temozolomide combined with bevacizumab in metastatic melanoma. A multicenter phase II trial (SAKK 50/07)
Von Moos, R., Seifert, B., Ochsenbein, A., Cathomas, R., Schlaeppi, M., Gillessen, S., Schuller, J. C., Michielin, O., Goldinger, S. and Dummer, R. (2009). Temozolomide combined with bevacizumab in metastatic melanoma. A multicenter phase II trial (SAKK 50/07). 15th ECCO/34th ESMO Multidisciplinary Congress, Berlin Germany, Sep 20-24, 2009. OXFORD: PERGAMON-ELSEVIER SCIENCE LTD. doi: 10.1016/S1359-6349(09)72059-2
2007
Journal Article
Combination of 308-nm xenon chloride excimer laser and topical calcipotriol in vitiligo
Goldinger, S. M., Dummer, R., Schmid, P., Burg, G., Seifert, B. and Lauchli, S. (2007). Combination of 308-nm xenon chloride excimer laser and topical calcipotriol in vitiligo. Journal of the European Academy of Dermatology and Venereology, 21 (4), 504-508. doi: 10.1111/j.1468-3083.2006.02016.x
2006
Journal Article
Excimer laser versus narrow-band UVB (311 nm) in the treatment of psoriasis vulgaris
Goldinger, Simone Maria, Dummer, Reinhard, Schmid, Peter, Vavricka, Mareike Prinz, Burg, Guenter and Laeuchli, Severin (2006). Excimer laser versus narrow-band UVB (311 nm) in the treatment of psoriasis vulgaris. Dermatology, 213 (2), 134-139. doi: 10.1159/000093852
Supervision
Availability
- Associate Professor Simone M Goldinger is:
- Available for supervision
Looking for a supervisor? Read our advice on how to choose a supervisor.
Media
Enquiries
For media enquiries about Associate Professor Simone M Goldinger's areas of expertise, story ideas and help finding experts, contact our Media team: